Journal of Society of Preventive Korean Medicine (대한예방한의학회지)

Society of Preventive Korean Medicine (대한예방한의학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib

  • Kang, Hyun-Gu (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Kang, Su-Jin (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Ku, Sae-Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Choi, Seong-Hun (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Lee, Young-Joon (Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University)
  • Received : 2019.03.23
  • Accepted : 2019.04.24
  • Published : 2019.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : This study investigated the effects of concentrated and lyophilized blue honeysuckle powders (BH) on the pharmacokinetics (PK) of sorafenib were observed. Method : The blood was collected at 0.5 hr before single oral treatment of sorafenib (40 mg/kg) or sorafenib with BH (400, 200 and 100 mg/kg) mixed formulas administration, and 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs after the end of single or mixed formula administration. Plasma concentrations of sorafenib were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, $t_{1/2}$ and $MRT_{inf}$ of sorafenib were analysis as compared with sorafenib single treatment. Results : Single oral administration of mixed formulas induced significant increases of plasma sorafenib concentrations from 0.5 hr after end of administration throughout all blood collected time points, as compared with sorafenib single formula treated rats, and significant decreases of sorafenib Tmax with increases of Cmax, $AUC_{0-t}$ and $AUC_{0-inf}$ were detected in sorafenib and BH 400 mg/kg mixed formulation treated rats as compared with sorafenib single formula treated rats, respectively. Inaddition, sorafenib and BH 200 or 100 mg/kg mixed formula treated rats also showed significant increases of sorafenib Cmax, $AUC_{0-t}$ and $AUC_{0-inf}$, respectively. Conclusions : According to these results, mixed formulation of BH with sorafenib increased the bioavailability of sorafenib through the increment of the absorptions.

Keywords

References

  1. Bayer. Nexavar (sorafenib tosylate) tablets prescribing information. West Haven, CT2007 Feb.
  2. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-240. https://doi.org/10.2165/00003495-200969020-00006
  3. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013
  4. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009;28(1):85-94. https://doi.org/10.1038/onc.2008.362
  5. Fabian P, Berkovcov? J. Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer. Cesk Patol. 2011;47(4):154-158.
  6. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011;135(6):698-703. https://doi.org/10.5858/2010-0523-RA.1
  7. Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem. 2012;19(7):938-944. https://doi.org/10.2174/092986712799320736
  8. Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100(3):328-330. https://doi.org/10.1097/SMJ.0b013e31802f01a9
  9. Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol. 2008;26(24):4047-4048. https://doi.org/10.1200/JCO.2008.18.3525
  10. Franck N, Barete S, Moguelet P, Blanchet B, Carlotti A, Ropert S, et al. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. J Clin Oncol. 2010;28(31):e640-642. https://doi.org/10.1200/JCO.2010.31.3783
  11. Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445. https://doi.org/10.1111/j.1365-2133.2011.10377.x
  12. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396-400. https://doi.org/10.1111/j.1529-8019.2011.01435.x
  13. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12(1):144-151. https://doi.org/10.1158/1078-0432.CCR-05-1571
  14. Ricciardi S, Mey V, Nannizzi S, Pasqualetti G, Crea F, Del Tacca M, et al. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy. 2010;56(4):303-312. https://doi.org/10.1159/000320031
  15. Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer. 2005;5(3):188-196. https://doi.org/10.3816/CCC.2005.n.030
  16. Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, et al. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther. 2003;41(12):618-619. https://doi.org/10.5414/CPP41618
  17. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15(19):6062-6069. https://doi.org/10.1158/1078-0432.CCR-09-0048
  18. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50(9):551-603. https://doi.org/10.2165/11593320-000000000-00000
  19. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011;68(5):1111-1118. https://doi.org/10.1007/s00280-011-1585-0
  20. Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, et al. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol. 2012;69(1):137-144. https://doi.org/10.1007/s00280-011-1674-0
  21. Moretti LV, Montalvo RO. Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm. 2009;66 (23):2123-2125. https://doi.org/10.2146/ajhp080436
  22. Kim SM, Lee CH, Park SJ, Kang SJ, Song CH, Han CH, et al. Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min. J Soc Preventive Korean Med. 2014;18(2):89-100.
  23. Lee CH, Kim SM, Kang SJ, Park SJ, Song CH, Han CH, et al. Effect of Gongjindangamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment. J Soc Preventive Korean Med. 2015;19(1):145-159.
  24. Svarcova I, Heinrich J, Valentova K. Berry fruits as a source of biologically active compounds: the case of Lonicera caerulea. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(2):163-174. https://doi.org/10.5507/bp.2007.031
  25. Chaovanalikit A, Thompson MM, Wrolstad RE. Characterization and quantification of anthocyanins and polyphenolics in blueh Honeysuckle (Lonicera caerulea L.). J Agric Food Chem. 2004;52(4):848-852. https://doi.org/10.1021/jf030509o
  26. Zhao H, Wang Z, Ma F, Yang X, Cheng C, Yao L. Protective effect of anthocyanin from Lonicera Caerulea var. Edulis on radiationinduced damage in mice. Int J Mol Sci. 2012;13(9):11773-11782. https://doi.org/10.3390/ijms130911773
  27. Jurgonski A, Juskiewicz J, Zdunczyk Z. An anthocyanin-rich extract from Kamchatka honeysuckle increases enzymatic activity within the gut and ameliorates abnormal lipid and glucose metabolism in rats. Nutrition. 2013;29(6):898-902. https://doi.org/10.1016/j.nut.2012.11.006
  28. Palikova I, Valentova K, Oborna I, Ulrichova J. Protectivity of blue honeysuckle extract against oxidative human endothelial cells and rat hepatocyte damage. J Agric Food Chem. 2009;57(15):6584-6589. https://doi.org/10.1021/jf9003994
  29. Jin XH, Ohgami K, Shiratori K, Suzuki Y, Koyama Y, Yoshida K, et al. Effects of blue honeysuckle (Lonicera caerulea L.) extract on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res. 2006;82(5):860-867. https://doi.org/10.1016/j.exer.2005.10.024
  30. Zdarilova A, Rajnochova Svobodova A, Chytilova K, Simanek V, Ulrichova J. Polyphenolic fraction of Lonicera caerulea L. fruits reduces oxidative stress and inflammatory markers induced by lipopolysaccharide in gingival fibroblasts. Food Chem Toxicol. 2010;48(6):1555-1561. https://doi.org/10.1016/j.fct.2010.03.024
  31. Chen L, Xin X, Yuan Q, Su D, Liu W. Phytochemical properties and antioxidant capacities of various colored berries. J Sci Food Agric. 2014;94(2):180-188. https://doi.org/10.1002/jsfa.6216
  32. Svobodova A, Rambouskova J, Walterova D, Vostalova J. Protective effects of phenolic fraction of blue honeysuckle fruits against UVA-induced damage to human keratinocytes. Arch Dermatol Res. 2008;300(5):225-233. https://doi.org/10.1007/s00403-008-0850-5
  33. Vostalova J, Galandakova A, Palikova I, Ulrichova J, Dolezal D, Lichnovska R, et al. Lonicera caerulea fruits reduce UVAinduced damage in hairless mice. J Photochem Photobiol B. 2013;128:1-11. https://doi.org/10.1016/j.jphotobiol.2013.07.024
  34. Kim HS, Park SI, Choi SH, Song CH, Park SJ, Shin YK, et al. Single oral dose toxicity test of blue honeysuckle concentrate in mice. Toxicol Res. 2015;31(1):61-68. https://doi.org/10.5487/TR.2015.31.1.061
  35. AOAC (Association of Official Analytical Chemists). Official Methods of Analysis International. 17th ed. Washington, DC.:AOAC; 2000.
  36. Singleton VL, Timberlake CF, Lea AGH. The phenolic cinnamates of white grapes and wine. J Sci Food Agric. 1978;29(4):403-410. https://doi.org/10.1002/jsfa.2740290416
  37. Yang J, Meyers KJ, van der Heide J, Liu RH. Varietal differences in phenolic content and antioxidant and antiproliferative activities of onions. J Agric Food Chem. 2004;52(22):6787-6793. https://doi.org/10.1021/jf0307144
  38. Boyles MJ, Wrolstad RE. Anthocyanin Composition of Red Raspberry Juice: Influences of Cultivar, Processing, and Environmental Factors. J Food Sci. 1993;58(5):1135-1141. https://doi.org/10.1111/j.1365-2621.1993.tb06132.x
  39. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel-Dekker; 1982.
  40. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988;16(3):303-309. https://doi.org/10.1007/BF01062139
  41. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1978;6(6):539-546. https://doi.org/10.1007/BF01062108
  42. Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011;419(1-2):339-346. https://doi.org/10.1016/j.ijpharm.2011.08.003
  43. Tod M, Mir O, Bancelin N, Coriat R, Thomas-Schoemann A, Taieb F, et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res. 2011;28(12):3199-3207. https://doi.org/10.1007/s11095-011-0499-1
  44. Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs. 2012;30(6):2096-2102. https://doi.org/10.1007/s10637-011-9767-5
  45. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11(11):1943-1955. https://doi.org/10.1517/14656566.2010.496453
  46. Kennoki T, Kondo T, Kimata N, Murakami J, Ishimori I, Nakazawa H, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol. 2011;41(5):647-655. https://doi.org/10.1093/jjco/hyr015
  47. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472-5480. https://doi.org/10.1158/1078-0432.CCR-04-2658
  48. Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs. 2012;30(5):1991-2000. https://doi.org/10.1007/s10637-011-9760-z
  49. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2007;37(10):755-762. https://doi.org/10.1093/jjco/hym095
  50. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008; 99(1):159-165.
  51. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99(7):1492-1498. https://doi.org/10.1111/j.1349-7006.2008.00837.x
  52. Sparidans RW, Vlaming ML, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(3):269-276. https://doi.org/10.1016/j.jchromb.2008.12.026